"Designing Growth Strategies is in our DNA"

C-Reactive Protein Testing Market Size, Share, Growth & COVID-19 Impact Analysis, By Product (Reagent & Kits and Instruments), By Assay Type (Chemiluminescence Immunoassay (CLIA), Enzyme-Linked Immunosorbent Assay (ELISA), Immunoturbidimetric Assay, and Others), By Detection Range (Conventional CRP and hs-CRP), By Setting (Laboratory Testing and Point-of-Care (POC) Testing), By End User (Hospitals & Clinics, Diagnostic Laboratories, and Others), and Regional Forecast, 2023-2030

Last Updated :April 01, 2024 | Format: PDF | Report ID: FBI107164

 

KEY MARKET INSIGHTS

The C-reactive protein testing market size was valued at USD 2.16 billion in 2022 and is projected to grow from USD 2.29 billion in 2023 to USD 3.29 billion by 2030, exhibiting a CAGR of 5.3% during 2023-2030. North America dominated the global market with a share of 34.72% in 2022.


C-reactive protein is considered a non-specific marker of inflammation. It plays an important role in predicting the risk of an individual suffering from a heart attack and stroke. Additionally, the level of C-reactive protein in the blood helps in the diagnosis of various chronic diseases, such as cancer, cardiovascular diseases, rheumatoid arthritis, and others.


The key factors driving the growth of the market include the rising prevalence of chronic diseases and increased usage of these tests during the COVID-19 pandemic. Additionally, increasing importance of C-reactive protein point-of-care tests while using antibiotics in primary care settings is also anticipated to drive the C-reactive protein testing market growth in future.



  • For instance, as per the data published by the Centers for Disease Control and Prevention (CDC) in October 2022, the number of adults aged 20 years and older suffering from Coronary Artery Disease (CAD) in the U.S. had reached 20.1 million. Furthermore, it was stated that an estimated 805,000 people in the U.S. suffer from a heart attack every year.


Thus, the increasing prevalence of cardiovascular diseases, cancer, autoimmune diseases, and others has raised the adoption and demand for C-reactive protein (CRP) test, in turn, driving the market growth during the forecast period. Furthermore, increasing focus of key players in the research and development of technologically advanced instruments and kits, such as point of care products for C-reactive protein testing is also expected to propel the market growth.


COVID-19 IMPACT 


High Usage of these Diagnostics in Determining Severity of Inflammation Propelled Market Development During Pandemic


The impact of COVID-19 pandemic on the C-reactive protein market growth was positive. The market witnessed a strong demand for products and services for CRP testing during the COVID-19 pandemic. In addition, several research studies were conducted to understand the role of C - reactive protein in terms of COVID-19 infection.



  • For instance, according to an article published in the International Journal of Epidemiology in March 2021, the levels of CRP can be used by clinicians as an early indicator for treatment decisions, enhanced observation, and advanced care planning.


Furthermore, several regulatory bodies were also in support of the usage of these tests as a marker for COVID-19 infection. For instance, the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) issued guidelines on COVID-19 Testing in Clinical Laboratories. In these guidelines, it stated C-reactive protein as one of the markers, which can be used to evaluate the severity of the infection and prognostic as well as therapeutic monitoring.


The market witnessed a decline in 2021 and 2022 due to slowdown in the number of these testing procedures; however, the market is anticipated to witness steady growth prospects henceforth.


LATEST TRENDS 


Request a Free sample to learn more about this report.


Growing Adoption of Point-of-Care (POC) CRP Tests to Guide Prescribing of Antibiotics


In recent years, C-reactive protein point-of-care testing has emerged as a promising diagnostic tool in terms of reducing antibiotic prescriptions. These tests are increasingly being promoted to enhance control on antibiotic and reduce diagnostic uncertainty. An increasing number of research studies are being conducted to evaluate the use of CRP POCT in primary care settings.



  • For instance, a research article was published in the British Journal of General Practice in February 2022, which demonstrated the implementation of the C-reactive protein POC testing for improved diagnosis of acute respiratory infections.

  • Similarly, another article published in BMC Health Services Research in February 2020 demonstrated a clinical study which was being conducted to evaluate whether the use of CRP point-of-care testing for suspected Lower Respiratory Tract Infection (LRTI) was effective in reducing antibiotic prescription in nursing homes.


Furthermore, to support the use of these point-of-care testing tools in primary and community care, in 2022, the Primary Care Respiratory Society published a guide to examine the application and evidence of these testing procedures. Such initiatives are anticipated to supplement the market growth in the coming years.


C-REACTIVE PROTEIN TESTING MARKET GROWTH FACTORS


Rising Prevalence of Chronic Diseases to Surge Demand for C-Reactive Protein Testing


The rising prevalence of chronic diseases is one of the major factors contributing to the increasing usage of these test kits globally. Chronic diseases linked to higher C-reactive protein levels include rheumatoid arthritis, inflammatory bowel disease, cancer, cardiovascular diseases, and others. With the rising prevalence of these diseases, CRP tests are being increasingly used to detect inflammation. Elevated CRP level is an indicator of chronic inflammation in the body.



  • For instance, according to the NCBI, in 2022, the number of new cancer cases was predicted to be 1,918,030 in the U.S. It was also predicted that cancer would be the cause of 609,360 deaths across the U.S. in the same year. Increased CRP levels are associated with the progression of ovarian, skin, and lung cancer.


Moreover, during the COVID-19 pandemic, CRP testing was recommended by doctors for patients with critical conditions as well as patients in home isolation. As these tests are not as costly as CT scans, it was recommended that these tests be conducted twice within four to five days to decide the further course of treatment. Thus, the above-mentioned factors are anticipated to drive the C-reactive protein testing market share throughout the forecast period.


Growing Focus of Key Players on New Product Launches to Propel Market Growth


The increasing efforts of market players on the development of new, technologically advanced products are expected to boost the expansion of the market during the forecast period.


These players are taking robust efforts to develop and launch innovative products. Their increasing focus on catering to the unmet demands of the rising patient population is expected to supplement the market growth in the coming years.


Moreover, the development of point-of-care tests by key companies is also expected to boost the market progress in the coming years.



  • For instance, in July 2022, Bloom Diagnostics, a Swiss meditech company, launched the Bloom Inflammation Test for the detection and quantitative determination of CRP levels. This test can be used with the Bloom system.


RESTRAINING FACTORS


Availability of Alternative Disease Diagnostics Methods to Limit Product Adoption


C-reactive protein is a non-specific marker of inflammation. Hence, this test is not useful for an accurate diagnosis of any disease. Thus, the fact that it is not a self-sufficient diagnostic test may impede the development of this market.


Furthermore, there is a vast presence of a number of different tests for the accurate diagnosis of a particular disease. For instance, high-accuracy tests, such as coronary CT angiography, electrocardiography (ECG or EKG), exercise cardiac stress test, and others, are available for the screening of cardiovascular diseases. Thus, the availability of such alternative disease diagnostic methods may limit the market’s growth to a certain extent.


SEGMENTATION


By Product Analysis


To know how our report can help streamline your business, Speak to Analyst


Increasing Number of CRP Tests Resulted in Growing Demand for Reagents & Kits throughout the Forecast Period


On the basis of product, the market is segmented into reagents & kits and instruments.


The reagents & kits segment accounted for the largest market share in 2022. This can be attributed to factors such as an increasing patient pool undergoing C-reactive protein testing for various conditions. The increasing number of market players offering various consumables, such as test kits, new product approvals, and introduction of innovative products, have also supported the segment’s growth.



  • For instance, in November 2022, LumiraDx launched the hs-CRP point-of-care antigen test in India. This test was aimed at reducing the unnecessary prescribing of antibiotics in the country.


The instruments segment is anticipated to witness significant growth throughout the forecast period. Increasing regulatory approvals for medical instruments is one of the key factors driving the segment’s growth during the forecast period.



  • For instance, in November 2022, the U.S. FDA approved the ProciseDx instrument and C reactive protein (CRP) test for the quantitative determination of C-reactive protein levels. This instrument is said to provide results in less than five minutes.


By Assay Type Analysis


Immunoturbidimetric Assays to Dominate Market Owing to Growing Presence of Products Equipped with this Technology


On the basis of assay type, the market is segmented into chemiluminescence immunoassay (CLIA), enzyme-linked immunosorbent assay (ELISA), immunoturbidimetric assay, and others.


The immunoturbidimetric assay segment dominated the C - reactive protein testing market share in 2022 owing to the presence of several products that use this technology. Increasing usage of these test kits among end-users also supports the dominance of this segment in the market. In addition, active involvement of the research community in the development of innovative assays will further support the segment’s growth.



  • For instance, a research study was published in the Journal of Clinical Chemistry and Laboratory Medicine in September 2020. In this study, researchers demonstrated the use of latex-enhanced immunoturbidimetric assay in the detection of CRP in human serum.


The Enzyme Linked Immunosorbent Assay (ELISA) segment captured a considerable share of the market in 2022. Several advantages offered by ELISA assays are supporting the increasing use of these assays in the market. These advantages include high specificity, low-cost, low detection limit, ease of preparation, ease of operation, and others.


In the field of clinical diagnostics, chemiluminescence immunoassay (CLIA)-based testing plays a significant role in the early detection of various chronic diseases. The high prevalence of chronic diseases will drive the demand for effective diagnostic methods such as CLIA. Various research studies are also being conducted to develop innovative CLIA-based testing kits. Other assay types are expected to witness slow growth over the forecast period owing to their slow adoption among the end-users.


By Detection Range Analysis


Rising Incidence of Chronic & Autoimmune Diseases to Support the Dominance of conventional CRP Segment


On the basis of detection range, the market is segmented into conventional CRP and hs-CRP.


The conventional CRP segment dominated the market in 2022. The rising prevalence of chronic and autoimmune diseases, such as rheumatoid arthritis, inflammatory bowel disease, and cancer among the population is one of the major factors driving the segment’s growth. Along with this, the growing number of initiatives for raising awareness about these diseases is increasing number of these tests being prescribed for the patient population.


The adoption of high-sensitivity CRP (hs-CRP) testing is rising amongst the patient population owing to the high prevalence of cardiovascular diseases across the globe. An hs-CRP test is widely used to predict the risk of heart disease among the population.



  • According to the U.S. Centers for Disease Control and Prevention (CDC), about 805,000 people in the U.S. suffer from a heart attack every year. Out of these, about 1 in 5 heart attacks are silent.


By Setting Analysis


High Preference of Laboratory Testing to Support the High Share of the Segment


On the basis of setting, the market is segmented into laboratory testing and Point-of-Care (POC) testing.


The laboratory testing segment dominated the market in 2022 and is expected to continue its dominance throughout the forecast period. This can be attributed to the detailed analysis provided by laboratory-based tests. It is considered a more precise method for measuring CRP levels. Laboratory testing includes testing in public health labs, commercial/private health laboratories, and hospital-associated laboratories.


The Point-of-Care (POC) testing segment is anticipated to witness high growth in the future. The factors contributing to this segment’s growth include growing adoption of POC testing in resource limited settings, new product launches, and increasing regulatory approvals for POC testing products.


By End User Analysis


Increasing Number of Diagnostic Testing in Laboratories to Support the High Share of Laboratory Testing Segment


On the basis of end user, the market is divided into hospitals & clinics, diagnostic laboratories, and others.


The diagnostic laboratories segment captured the largest share of the market in 2022. This is majorly due to the increasing awareness about chronic diseases, use of CRP in various medical conditions, and increasing number of test orders by healthcare professionals. Furthermore, the COVID-19 pandemic also boosted the segment’s growth due to increased hospitalizations and use of these tests in determining the severity of the SARS-CoV-2 infection.


The hospitals & clinics segment is projected to witness notable growth throughout the forecast period. This can be attributed to the increasing number of hospital visits and hospital stays, especially in developing countries due to high prevalence of chronic conditions.



  • For instance, according to the National Center for Health Statistics, updated as of February 2023, 18.6 million individuals in the U.S. were admitted in hospitals through emergency room visits in 2020.


REGIONAL INSIGHTS


North America C-Reactive Protein Testing Market Size, 2022 (USD billion)

To get more information on the regional analysis of this market, Request a Free sample


On the basis of region, North America captured the largest C-reactive protein testing market share and generated a revenue of USD 0.75 billion in 2022. The region is estimated to dominate the market throughout the forecast period. This can be attributed to the high prevalence of chronic diseases in the U.S., availability of innovative products, and high focus on clinical research in the region.



  • For instance, according to CDC estimates, six in ten individuals in the U.S. have a chronic disease and four in ten individuals have two or more than two chronic diseases.


Moreover, increasing healthcare expenditure to support chronic disease care in the region and presence of favorable reimbursement policies will further supplement the dominance of the region in the global market.



  • According to the American Action Forum, the average direct healthcare cost for an individual suffering from a chronic disease is USD 6,032. This is approximately 5 times higher than that of an individual without chronic disease.


Europe accounted for the second largest share in the global market. High usage of C-reactive protein testing for a specific disease, supportive regulatory framework, and increasing number of new products receiving CE marking are some of the factors driving the Europe market growth.



  • According to an article published in the National Center for Biotechnology Information (NCBI) in January 2022, in Europe, C-reactive protein testing is conducted more frequently and used to diagnose and monitor psoriatic arthritis (PsA).


The market in Asia Pacific is expected to record the highest CAGR during the forecast period owing to the rising prevalence of chronic diseases that require these diagnostic procedures. In addition, increasing strategic initiatives by the market leaders to expand their product portfolios and growing awareness among the population are some other factors that might support the regional market’s growth throughout the forecast period.



  • For instance, in March 2017, SD Biosensor Inc. collaborated with FIND to develop a Rapid Diagnostic Test (RDT) that can simultaneously detect C-reactive protein and malaria infection in a patient’s blood. Such products were said to be suitable for managing the disease rate in low and middle-income countries.


Furthermore, the markets in Latin America and Middle East & Africa are expected to witness moderate growth during the forecast period. Factors, such as increasing focus of market players and government authorities on establishing advanced testing facilities and launches of new products, are responsible for the growth of the market in these region.  


KEY INDUSTRY PLAYERS


Abbott Inc., to Lead Market Growth with Strong Product Portfolio


This market is highly fragmented and competitive owing to the presence of a large number of leading market players that are offering testing kits and instruments. These companies also witnessed a significant growth in their revenues due to the increased demand for CRP testing during the COVID-19 pandemic.


Abbott is one of the leading players in this market. The company has a broad portfolio, which includes both reagents & kits and instruments for these testing procedures. With the acquisition of Alere Inc. in February 2016, the company expanded its POC testing portfolio including C-reactive protein testing products. The growing investment of other prominent players, such as Thermo Fisher Scientific, F. Hoffmann-La Roche Ltd., Quest Diagnostics, CTK Biotech Inc., and others, in research and development activities for the development of innovative C-reactive protein testing products is also contributing to the intense competition in the market. These firms are also focusing on expanding their customer base through various initiatives.



  • For instance, in March 2021, Boditech Med announced its plans to construct a new R & D center in South Korea.


LIST OF KEY COMPANIES PROFILED IN C-REACTIVE PROTEIN TESTING MARKET:



KEY INDUSTRY DEVELOPMENTS



  • February 2023 - Qlife Holding AB launched Egoo CRP test in Sweden. This test was a soft-launch and will be followed by the submission of application for the CE mark.

  • December 2022 - Siemens Healthcare Diagnostics Products GmbH received 510(k) clearance for its CardioPhase hs-CRP prognostic test from the U.S. FDA.

  • March 2022 – Novo Integrated Sciences, Inc. and Boditech Med Inc. signed a Memorandum of Understanding (MoU) for the launch and deployment of the latter’s IVD solutions and technologies in North America.

  • October 2020Nova Biomedical introduced the Allegro CRP Test, which can be used for point-of-care (POC) testing in primary care settings. This product was launched in countries accepting the CE mark.

  • September 2017 - VTT Technical Research Centre of Finland developed a portable, home-use device to measure inflammation levels. This device provides CRP levels in numeric forms.


REPORT COVERAGE


An Infographic Representation of C-Reactive Protein Testing Market

To get information on various segments, share your queries with us



The global C-reactive protein testing market research report provides an in-depth analysis of the industry. It focuses on market segments such as product, assay type, detection range, setting, and end-user. Besides this, it offers an analysis related to the market overview, the impact of COVID-19, and latest market trends. Additionally, the report consists of several factors that have contributed to the market growth. The report also provides competitive landscape of the global market.


Report Scope & Segmentation 


































































  ATTRIBUTE



  DETAILS



Study Period



2019-2030



Base Year



2022



Estimated Year



2023



Forecast Period



2023-2030



Historical Period



2019-2021



Growth Rate



CAGR of 5.3% from 2023-2030



Unit



Value (USD billion)



Segmentation



By Product, Assay Type, Detection Range, Setting, End User, and Region



By Product




  • Reagents & Kits

  • Instruments



By Assay Type




  • Chemiluminescence Immunoassay (CLIA)

  • Enzyme-Linked Immunosorbent Assay (ELISA)

  • Immunoturbidimetric Assay

  • Others



By Detection Range




  • Conventional CRP

  • hs-CRP



By Setting


 




  • Laboratory Testing

  • Point-of-Care (POC) Testing



By End User




  • Hospitals & Clinics

  • Diagnostic Laboratories

  • Others



By Region




  • North America (By Product, By Assay Type, By Detection Range, By Setting, By End User, By Country)

    • U.S.

    • Canada



  • Europe (By Product, By Assay Type, By Detection Range, By Setting, By End User, By Country/Sub-Region)

    • Germany

    • U.K.

    • France

    • Italy

    • Spain

    • Rest of Europe



  • Asia Pacific (By Product, By Assay Type, By Detection Range, By Setting, By End User, By Country/Sub-Region)

    • China

    • Japan

    • India

    • Australia

    • Rest of Asia Pacific



  • Latin America (By Product, By Assay Type, By Detection Range, By Setting, By End User, By Country/Sub-Region)

    • Brazil

    • Mexico

    • Rest of Latin America



  • Middle East & Africa (By Product, By Assay Type, By Detection Range, By Setting, By End User, By Country/Sub-Region)

    • GCC

    • South Africa

    • Rest of Middle East & Africa








Frequently Asked Questions

Fortune Business Insights says that the global market stood at USD 2.16 billion in 2022 and is projected to reach USD 3.29 billion by 2030.

The market will exhibit a steady CAGR of 5.3% during the forecast period of 2023-2030.

Currently, the immunoturbidimetric assay segment is leading the market by assay type.

Rising prevalence of chronic diseases, increasing research & development activities by major market players, rising number of approvals, and launch of innovative POC products are the key drivers of the market.

Abbott, F. Hoffmann-La Roche Ltd., Siemens Healthcare Private Limited, Quest Diagnostics Incorporated, and Thermo Fisher Scientific, Inc. are the major players in the market.

North America dominated the market in 2022.

Surge in demand for effective treatment of infectious diseases, increased adoption of technologically advanced diagnostic testing, and a considerable patient population base are some of the factors expected to drive the adoption of these products.

Seeking Comprehensive Intelligence on Different Markets?
Get in Touch with Our Experts

Speak to an Expert
  • 2019-2030
  • 2022
  • 2019-2021
  • 180

Personalize this Research

  • Granular Research on Specified Regions or Segments
  • Companies Profiled based on User Requirement
  • Broader Insights Pertaining to a Specific Segment or Region
  • Breaking Down Competitive Landscape as per Your Requirement
  • Other Specific Requirement on Customization
Request Customization Banner

Client Testimonials

“This report is really well done and we really appreciate it! Again, I may have questions as we dig in deeper. Thanks again for some really good work.”

- U.S.-based biotechnology company focussing on treatment of chronic pain.

“Kudos to your team. Thank you very much for your support and agility to answer our questions.”

- Europe-based provider of solutions to automate data centre operations.

“We appreciate you and your team taking out time to share the report and data file with us, and we are grateful for the flexibility provided to modify the document as per request. This does help us in our business decision making. We would be pleased to work with you again, and hope to continue our business relationship long into the future.”

- India-based manufacturer of industrial and specialty intermediates with a strong global presence.

“I want to first congratulate you on the great work done on the Medical Platforms project. Thank you so much for all your efforts.”

- One of the largest cosmetics company in the world.

“Thank you very much. I really appreciate the work your team has done. I feel very comfortable recommending your services to some of the other startups that I’m working with, and will likely establish a good long partnership with you.”

- U.S. based startup operating in the cultivated meat market.

“We received the below report on the U.S. market from you. We were very satisfied with the report.”

- Global hearing aids manufacturer.

“I just finished my first pass-through of the report. Great work! Thank you!”

- U.S. based solar racking solutions provider.

“Thanks again for the great work on our last partnership. We are ramping up a new project to understand the imaging and imaging service and distribution market in the U.S.”

- World’s leading advisory firm.

“We feel positive about the results. Based on the presented results, we will do strategic review of this new information and might commission a detailed study on some of the modules included in the report after end of the year. Overall we are very satisfied and please pass on the praise to the team. Thank you for the co-operation!”

- Germany based machine construction company.

“Thank you very much for the very good report. I have another requirement on cutting tools, paper crafts and decorative items.”

- Japanese manufacturing company of stationery products.

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.
X